Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.45 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13928204 | 0.89 | MMP13 (0.51) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL3253196 | 0.88 | MMP2 (0.53) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL13928203 | 0.85 | BRD4 (0.53) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL3254754 | 0.84 | GABRA1 (0.47) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL3251011 | 0.84 | GABRA1 (0.47) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL3248855 | 0.84 | GABRA1 (0.64) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL3253875 | 0.84 | GABRA1 (0.50) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL3250224 | 0.84 | CYP1A2 (0.42) | CYP1A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3244737 | 0.83 | ALDH1A1 (0.56) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL3255461 | 0.83 | BRD4 (0.52) | ALDH1A1MEN1KMT2AHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899335-B1 | PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PF MEDICAMENT (FR) | 2010-05-19 | — | — | EP | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
| WO-2007003611-A1 | PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | GABRA1 3395/4885GABRB2 2245/4885GABRB1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.